{
    "clinical_study": {
        "@rank": "99304", 
        "acronym": "ZIPANG", 
        "arm_group": [
            {
                "arm_group_label": "Z-360 60mg+Gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "Z-360 60 mg will be taken orally, twice daily (BID) after a meal."
            }, 
            {
                "arm_group_label": "Z-360 120mg+Gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "Z-360 120 mg will be taken orally, twice daily (BID) after a meal."
            }, 
            {
                "arm_group_label": "Z-360 240mg+Gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "Z-360 240 mg will be taken orally, twice daily (BID) after a meal."
            }, 
            {
                "arm_group_label": "Placebo+Gemcitabine", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be taken orally, twice daily (BID) after a meal."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM\n      plus placebo on the overall survival (OS) in subjects with metastatic Pancreatic\n      Adenocarcinoma."
        }, 
        "brief_title": "Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Pancreatic Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Subjects with histological or cytological evidence of metastatic Pancreatic\n             Adenocarcinoma, Measurable disease or non-measurable disease by Response Evaluation\n             Criteria in Solid Tumors (RECIST) version criteria\n\n          -  2. Subjects with a life expectancy of at least 12 weeks,\n\n          -  3. Subjects with an Eastern cooperative oncology group performance status (ECOG PS)\n             of 0, 1 or 2,\n\n          -  4. Subjects with the following adequate organ functions:\n\n               -  White blood cell count \u22653,000/\u03bcL (or absolute neutrophil count \u22651,500/\u03bcL) and \u2264\n                  12,000/\u03bcL ,\n\n               -  Platelet count \u2265100.0 \u00d7 10^9/L,\n\n               -  Hemoglobin \u22659.0 g/dL,\n\n               -  Serum creatinine \u22641.5 \u00d7 the upper limit normal (ULN),\n\n               -  Total bilirubin \u22642.0 \u00d7 ULN,\n\n               -  Serum aspartate transaminase levels \u22643.0 \u00d7 ULN (\u22645.0 \u00d7 ULN in presence of liver\n                  metastases), and\n\n               -  Serum alanine aminotransferase levels \u22643.0 \u00d7 ULN (\u22645.0 \u00d7 ULN in presence of\n                  liver metastases).\n\n        Exclusion Criteria:\n\n          -  Subjects received the following previous therapies for Pancreatic Adenocarcinoma:\n\n               -  Surgery within the 4 weeks prior to randomization,\n\n               -  Radiation and chemoradiation within the 12 weeks prior to randomization,\n\n               -  Radiation for pain relief within the 4 weeks prior to randomization,\n\n               -  Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks\n                  prior to randomization,\n\n               -  Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior\n                  to randomization,\n\n               -  Gemcitabine \u2265600 mg/m^2 as sensitizer for chemoradiation,\n\n               -  Gemcitabine <600 mg/m^2 as sensitizer for chemoradiation within the 12 weeks\n                  prior to randomization,\n\n               -  Gemcitabine used for systemic chemotherapy, or\n\n               -  Systemic chemotherapies except GEM within the 4 weeks prior to randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117258", 
            "org_study_id": "Z-360-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Z-360 60mg+Gemcitabine", 
                    "Z-360 120mg+Gemcitabine", 
                    "Z-360 240mg+Gemcitabine"
                ], 
                "description": "Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.", 
                "intervention_name": "Z-360", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo+Gemcitabine", 
                "description": "Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Z-360, Pancreatic cancer, Pancreatic Adenocarcinoma", 
        "lastchanged_date": "April 26, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Zeria Investigator", 
                    "phone": "+81-356447053"
                }, 
                "facility": {
                    "address": {
                        "city": "Japan", 
                        "country": "Japan"
                    }, 
                    "name": "Zeria Investigative sites"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zeria Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Korea", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Zeria Investigative Sites"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zeria Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Taiwan", 
                        "country": "Taiwan"
                    }, 
                    "name": "Zeria Investigative Sites"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )", 
        "overall_contact": {
            "last_name": "Zeria Investigator", 
            "phone": "+81356447053"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Korea: Ministry of Food and Drug Safety", 
                "Taiwan : Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117258"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 24 months"
            }, 
            {
                "measure": "Time to Treatment Failure", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 24 months"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 months"
            }, 
            {
                "description": "Incidence of SAEs and AEs, laboratory test results, vital signs, ECG results and physical examination findings", 
                "measure": "Safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 24 months"
            }, 
            {
                "description": "To characterize the plasma pK of Z-360 when given in combination with GEM", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day1"
            }, 
            {
                "measure": "Response Rate", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 24 months"
            }, 
            {
                "measure": "Benefit Rate", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 months"
            }
        ], 
        "source": "Zeria Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zeria Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}